Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyMethallenestril
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Methallenestril
- Accession Number
- DB13143
- Type
- Small Molecule
- Groups
- Experimental
- Description
- Not Available
- Structure
Structure for DB13143 (Methallenestril)
- Synonyms
- b-ethyl-6-methoxy-a,a-dimethyl-2-naphthalenepropionic acid
- International/Other Brands
- Vallestril
- Categories
- UNII
- XL025389JS
- CAS number
- 517-18-0
- Weight
- Average: 286.371
Monoisotopic: 286.156894568 - Chemical Formula
- C18H22O3
- InChI Key
- KHLJKRBMZVNZOC-MRXNPFEDSA-N
- InChI
- InChI=1S/C18H22O3/c1-5-16(18(2,3)17(19)20)14-7-6-13-11-15(21-4)9-8-12(13)10-14/h6-11,16H,5H2,1-4H3,(H,19,20)/t16-/m1/s1
- IUPAC Name
- (3R)-3-(6-methoxynaphthalen-2-yl)-2,2-dimethylpentanoic acid
- SMILES
- CC[[email protected]](C1=CC=C2C=C(OC)C=CC2=C1)C(C)(C)C(O)=O
Pharmacology
- Indication
- Not Available
- Structured Indications
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 1,10-Phenanthroline The serum concentration of Methallenestril can be decreased when it is combined with 1,10-Phenanthroline. Experimental 16-Bromoepiandrosterone The serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Methallenestril. Investigational 19-norandrostenedione The serum concentration of 19-norandrostenedione can be increased when it is combined with Methallenestril. Experimental, Illicit 3,4-Dichloroisocoumarin The serum concentration of Methallenestril can be decreased when it is combined with 3,4-Dichloroisocoumarin. Experimental 4-(2-Aminoethyl)Benzenesulfonyl Fluoride The serum concentration of Methallenestril can be decreased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride. Experimental 5-androstenedione The serum concentration of 5-androstenedione can be increased when it is combined with Methallenestril. Experimental, Illicit Abciximab Methallenestril may decrease the anticoagulant activities of Abciximab. Approved Acenocoumarol Methallenestril may decrease the anticoagulant activities of Acenocoumarol. Approved, Investigational Acitretin The therapeutic efficacy of Methallenestril can be decreased when used in combination with Acitretin. Approved Adapalene The therapeutic efficacy of Methallenestril can be decreased when used in combination with Adapalene. Approved Alclometasone The serum concentration of Alclometasone can be increased when it is combined with Methallenestril. Approved Aldosterone The serum concentration of Aldosterone can be increased when it is combined with Methallenestril. Experimental, Investigational Alitretinoin The therapeutic efficacy of Methallenestril can be decreased when used in combination with Alitretinoin. Approved, Investigational Alogliptin The serum concentration of Methallenestril can be decreased when it is combined with Alogliptin. Approved Alpha-1-proteinase inhibitor The serum concentration of Methallenestril can be decreased when it is combined with Alpha-1-proteinase inhibitor. Approved Ambroxol acefyllinate The serum concentration of Ambroxol acefyllinate can be increased when it is combined with Methallenestril. Experimental, Investigational Amcinonide The serum concentration of Amcinonide can be increased when it is combined with Methallenestril. Approved Aminophylline The serum concentration of Aminophylline can be increased when it is combined with Methallenestril. Approved Amobarbital The therapeutic efficacy of Methallenestril can be decreased when used in combination with Amobarbital. Approved, Illicit Amprenavir The serum concentration of Methallenestril can be decreased when it is combined with Amprenavir. Approved, Investigational Anastrozole The therapeutic efficacy of Anastrozole can be decreased when used in combination with Methallenestril. Approved, Investigational Ancrod Methallenestril may decrease the anticoagulant activities of Ancrod. Approved, Investigational Androstenedione The serum concentration of Androstenedione can be increased when it is combined with Methallenestril. Experimental, Illicit Anecortave The serum concentration of Anecortave can be increased when it is combined with Methallenestril. Investigational anecortave acetate The serum concentration of anecortave acetate can be increased when it is combined with Methallenestril. Investigational Anthrax immune globulin human Methallenestril may increase the thrombogenic activities of Anthrax immune globulin human. Approved Antithrombin III human The serum concentration of Methallenestril can be decreased when it is combined with Antithrombin III human. Approved Apixaban The serum concentration of Methallenestril can be decreased when it is combined with Apixaban. Approved Aprepitant The serum concentration of Methallenestril can be decreased when it is combined with Aprepitant. Approved, Investigational Aprotinin The serum concentration of Methallenestril can be decreased when it is combined with Aprotinin. Approved, Investigational, Withdrawn Ardeparin Methallenestril may decrease the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban The serum concentration of Methallenestril can be decreased when it is combined with Argatroban. Approved, Investigational Armodafinil The serum concentration of Methallenestril can be decreased when it is combined with Armodafinil. Approved, Investigational Artemether The serum concentration of Methallenestril can be decreased when it is combined with Artemether. Approved Asunaprevir The serum concentration of Methallenestril can be decreased when it is combined with Asunaprevir. Approved, Investigational, Withdrawn Atamestane The serum concentration of Atamestane can be increased when it is combined with Methallenestril. Investigational Atazanavir The serum concentration of Methallenestril can be decreased when it is combined with Atazanavir. Approved, Investigational Barbexaclone The therapeutic efficacy of Methallenestril can be decreased when used in combination with Barbexaclone. Experimental Barbital The therapeutic efficacy of Methallenestril can be decreased when used in combination with Barbital. Illicit Batimastat The serum concentration of Methallenestril can be decreased when it is combined with Batimastat. Experimental Becaplermin Methallenestril may decrease the anticoagulant activities of Becaplermin. Approved, Investigational Beclomethasone dipropionate The serum concentration of Beclomethasone dipropionate can be increased when it is combined with Methallenestril. Approved, Investigational Benazepril The serum concentration of Methallenestril can be decreased when it is combined with Benazepril. Approved, Investigational Benzamidine The serum concentration of Methallenestril can be decreased when it is combined with Benzamidine. Experimental Betamethasone The serum concentration of Betamethasone can be increased when it is combined with Methallenestril. Approved, Vet Approved Bexarotene The serum concentration of Methallenestril can be decreased when it is combined with Bexarotene. Approved, Investigational Bivalirudin The serum concentration of Methallenestril can be decreased when it is combined with Bivalirudin. Approved, Investigational Boceprevir The serum concentration of Methallenestril can be decreased when it is combined with Boceprevir. Approved, Withdrawn Bosentan The serum concentration of Methallenestril can be decreased when it is combined with Bosentan. Approved, Investigational Budesonide The serum concentration of Budesonide can be increased when it is combined with Methallenestril. Approved Camostat The serum concentration of Methallenestril can be decreased when it is combined with Camostat. Experimental Candoxatril The serum concentration of Methallenestril can be decreased when it is combined with Candoxatril. Experimental Candoxatrilat The serum concentration of Methallenestril can be decreased when it is combined with Candoxatrilat. Experimental Capromab pendetide Methallenestril may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Captopril The serum concentration of Methallenestril can be decreased when it is combined with Captopril. Approved Carbamazepine The therapeutic efficacy of Methallenestril can be decreased when used in combination with Carbamazepine. Approved, Investigational Celecoxib Celecoxib may increase the thrombogenic activities of Methallenestril. Approved, Investigational Certoparin Methallenestril may decrease the anticoagulant activities of Certoparin. Approved, Investigational Chenodeoxycholic acid The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Methallenestril. Approved Cholesterol The serum concentration of Methallenestril can be decreased when it is combined with Cholesterol. Approved, Experimental, Investigational Cholestyramine The serum concentration of Methallenestril can be decreased when it is combined with Cholestyramine. Approved, Investigational Chymostatin The serum concentration of Methallenestril can be decreased when it is combined with Chymostatin. Experimental Ciclesonide The serum concentration of Ciclesonide can be increased when it is combined with Methallenestril. Approved, Investigational Cilastatin The serum concentration of Methallenestril can be decreased when it is combined with Cilastatin. Approved, Investigational Cilazapril The serum concentration of Methallenestril can be decreased when it is combined with Cilazapril. Approved Citric Acid Methallenestril may decrease the anticoagulant activities of Citric Acid. Approved, Nutraceutical, Vet Approved Clobazam The serum concentration of Methallenestril can be decreased when it is combined with Clobazam. Approved, Illicit Clobetasol The serum concentration of Clobetasol can be increased when it is combined with Methallenestril. Approved, Investigational Clobetasol propionate The serum concentration of Clobetasol propionate can be increased when it is combined with Methallenestril. Approved Clobetasone The serum concentration of Clobetasone can be increased when it is combined with Methallenestril. Approved Clocortolone The serum concentration of Clocortolone can be increased when it is combined with Methallenestril. Approved Clorindione Methallenestril may decrease the anticoagulant activities of Clorindione. Experimental Cobicistat The serum concentration of Methallenestril can be decreased when it is combined with Cobicistat. Approved Colesevelam The serum concentration of Methallenestril can be decreased when it is combined with Colesevelam. Approved Colestipol The serum concentration of Methallenestril can be decreased when it is combined with Colestipol. Approved Conestat alfa Methallenestril may increase the thrombogenic activities of Conestat alfa. Approved, Investigational Cortexolone 17α-propionate The serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Methallenestril. Investigational Corticosterone The serum concentration of Corticosterone can be increased when it is combined with Methallenestril. Experimental Cortisone acetate The serum concentration of Cortisone acetate can be increased when it is combined with Methallenestril. Approved, Investigational Dabigatran etexilate The serum concentration of Methallenestril can be decreased when it is combined with Dabigatran etexilate. Approved Dabrafenib The serum concentration of Methallenestril can be decreased when it is combined with Dabrafenib. Approved, Investigational Dalteparin Methallenestril may decrease the anticoagulant activities of Dalteparin. Approved Danaparoid Methallenestril may decrease the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban The serum concentration of Methallenestril can be decreased when it is combined with Darexaban. Investigational Darunavir The serum concentration of Methallenestril can be decreased when it is combined with Darunavir. Approved Deflazacort The serum concentration of Deflazacort can be increased when it is combined with Methallenestril. Approved, Investigational Delanzomib The serum concentration of Methallenestril can be decreased when it is combined with Delanzomib. Investigational Delapril The serum concentration of Methallenestril can be decreased when it is combined with Delapril. Experimental Desirudin Methallenestril may decrease the anticoagulant activities of Desirudin. Approved Desonide The serum concentration of Desonide can be increased when it is combined with Methallenestril. Approved, Investigational Desoximetasone The serum concentration of Desoximetasone can be increased when it is combined with Methallenestril. Approved Desoxycorticosterone acetate The serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Methallenestril. Approved Desoxycorticosterone Pivalate The serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Methallenestril. Experimental, Vet Approved Dexamethasone The serum concentration of Dexamethasone can be increased when it is combined with Methallenestril. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Methallenestril. Vet Approved Dextran Methallenestril may decrease the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dextran 40 Methallenestril may decrease the anticoagulant activities of Dextran 40. Approved Dextran 70 Methallenestril may decrease the anticoagulant activities of Dextran 70. Approved Dextran 75 Methallenestril may decrease the anticoagulant activities of Dextran 75. Approved Dicoumarol Methallenestril may decrease the anticoagulant activities of Dicoumarol. Approved Diflorasone The serum concentration of Diflorasone can be increased when it is combined with Methallenestril. Approved Difluocortolone The serum concentration of Difluocortolone can be increased when it is combined with Methallenestril. Approved, Investigational, Withdrawn Difluprednate The serum concentration of Difluprednate can be increased when it is combined with Methallenestril. Approved Diphenadione Methallenestril may decrease the anticoagulant activities of Diphenadione. Experimental Dyphylline The serum concentration of Dyphylline can be increased when it is combined with Methallenestril. Approved Ecabet The serum concentration of Methallenestril can be decreased when it is combined with Ecabet. Approved, Investigational Edetic Acid Methallenestril may decrease the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban The serum concentration of Methallenestril can be decreased when it is combined with Edoxaban. Approved Elafin The serum concentration of Methallenestril can be decreased when it is combined with Elafin. Investigational Elvitegravir The serum concentration of Methallenestril can be decreased when it is combined with Elvitegravir. Approved Enalapril The serum concentration of Methallenestril can be decreased when it is combined with Enalapril. Approved, Vet Approved Enalaprilat The serum concentration of Methallenestril can be decreased when it is combined with Enalaprilat. Approved Enalkiren The serum concentration of Methallenestril can be decreased when it is combined with Enalkiren. Experimental Enoxaparin Methallenestril may decrease the anticoagulant activities of Enoxaparin. Approved Epigallocatechin Gallate The serum concentration of Methallenestril can be decreased when it is combined with Epigallocatechin Gallate. Investigational Equilenin The serum concentration of Equilenin can be increased when it is combined with Methallenestril. Experimental Equilin The serum concentration of Equilin can be increased when it is combined with Methallenestril. Approved Eslicarbazepine acetate The serum concentration of Methallenestril can be decreased when it is combined with Eslicarbazepine acetate. Approved Estrone The serum concentration of Estrone can be increased when it is combined with Methallenestril. Approved Estrone sulfate The serum concentration of Estrone sulfate can be increased when it is combined with Methallenestril. Approved Ethyl biscoumacetate Methallenestril may decrease the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etodolac Etodolac may increase the thrombogenic activities of Methallenestril. Approved, Investigational, Vet Approved Etoricoxib Etoricoxib may increase the thrombogenic activities of Methallenestril. Approved, Investigational Exemestane The therapeutic efficacy of Exemestane can be decreased when used in combination with Methallenestril. Approved, Investigational Exenatide The serum concentration of Methallenestril can be decreased when it is combined with Exenatide. Approved, Investigational Faldaprevir The serum concentration of Methallenestril can be decreased when it is combined with Faldaprevir. Investigational Felbamate The serum concentration of Methallenestril can be decreased when it is combined with Felbamate. Approved Ferulic acid Methallenestril may decrease the anticoagulant activities of Ferulic acid. Experimental Flibanserin The serum concentration of Flibanserin can be increased when it is combined with Methallenestril. Approved, Investigational Fluasterone The serum concentration of Fluasterone can be increased when it is combined with Methallenestril. Investigational Fludrocortisone The serum concentration of Fludrocortisone can be increased when it is combined with Methallenestril. Approved, Investigational Fluindione Methallenestril may decrease the anticoagulant activities of Fluindione. Approved, Investigational Flumethasone The serum concentration of Flumethasone can be increased when it is combined with Methallenestril. Approved, Vet Approved Flunisolide The serum concentration of Flunisolide can be increased when it is combined with Methallenestril. Approved, Investigational Fluocinolone Acetonide The serum concentration of Fluocinolone Acetonide can be increased when it is combined with Methallenestril. Approved, Investigational, Vet Approved Fluocinonide The serum concentration of Fluocinonide can be increased when it is combined with Methallenestril. Approved, Investigational Fluocortolone The serum concentration of Fluocortolone can be increased when it is combined with Methallenestril. Approved, Withdrawn Fluorometholone The serum concentration of Fluorometholone can be increased when it is combined with Methallenestril. Approved, Investigational Fluprednidene The serum concentration of Fluprednidene can be increased when it is combined with Methallenestril. Approved, Withdrawn Fluprednisolone The serum concentration of Fluprednisolone can be increased when it is combined with Methallenestril. Approved Flurandrenolide The serum concentration of Flurandrenolide can be increased when it is combined with Methallenestril. Approved Fluticasone furoate The serum concentration of Fluticasone furoate can be increased when it is combined with Methallenestril. Approved Fluticasone propionate The serum concentration of Fluticasone propionate can be increased when it is combined with Methallenestril. Approved Fondaparinux Methallenestril may decrease the anticoagulant activities of Fondaparinux. Approved, Investigational Fondaparinux sodium Methallenestril may decrease the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Formestane The serum concentration of Formestane can be increased when it is combined with Methallenestril. Approved, Investigational, Withdrawn Fosamprenavir The serum concentration of Methallenestril can be decreased when it is combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Methallenestril can be decreased when it is combined with Fosaprepitant. Approved Fosinopril The serum concentration of Methallenestril can be decreased when it is combined with Fosinopril. Approved Fosphenytoin The therapeutic efficacy of Methallenestril can be decreased when used in combination with Fosphenytoin. Approved, Investigational Gabexate The serum concentration of Methallenestril can be decreased when it is combined with Gabexate. Investigational Geldanamycin The serum concentration of Methallenestril can be decreased when it is combined with Geldanamycin. Experimental, Investigational GM6001 The serum concentration of Methallenestril can be decreased when it is combined with GM6001. Experimental Griseofulvin The metabolism of Methallenestril can be increased when combined with Griseofulvin. Approved, Investigational, Vet Approved Halcinonide The serum concentration of Halcinonide can be increased when it is combined with Methallenestril. Approved, Investigational, Withdrawn HE3286 The serum concentration of HE3286 can be increased when it is combined with Methallenestril. Investigational Heparin Methallenestril may decrease the anticoagulant activities of Heparin. Approved, Investigational Hexobarbital The therapeutic efficacy of Methallenestril can be decreased when used in combination with Hexobarbital. Approved Human C1-esterase inhibitor Methallenestril may increase the thrombogenic activities of Human C1-esterase inhibitor. Approved Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methallenestril. Approved, Investigational Hydrocortisone The serum concentration of Hydrocortisone can be increased when it is combined with Methallenestril. Approved, Vet Approved Idraparinux The serum concentration of Methallenestril can be decreased when it is combined with Idraparinux. Investigational Imidapril The serum concentration of Methallenestril can be decreased when it is combined with Imidapril. Investigational Indinavir The serum concentration of Methallenestril can be decreased when it is combined with Indinavir. Approved Isoflurophate The serum concentration of Methallenestril can be decreased when it is combined with Isoflurophate. Approved, Investigational, Withdrawn Isotretinoin The therapeutic efficacy of Methallenestril can be decreased when used in combination with Isotretinoin. Approved Istaroxime The serum concentration of Istaroxime can be increased when it is combined with Methallenestril. Investigational Ixazomib The serum concentration of Methallenestril can be decreased when it is combined with Ixazomib. Approved, Investigational Lamotrigine The serum concentration of Lamotrigine can be decreased when it is combined with Methallenestril. Approved, Investigational Lenalidomide Methallenestril may increase the thrombogenic activities of Lenalidomide. Approved Lepirudin The serum concentration of Methallenestril can be decreased when it is combined with Lepirudin. Approved Letaxaban The serum concentration of Methallenestril can be decreased when it is combined with Letaxaban. Investigational Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Methallenestril. Approved Linagliptin The serum concentration of Methallenestril can be decreased when it is combined with Linagliptin. Approved Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Methallenestril. Approved, Vet Approved Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Methallenestril. Approved Lisinopril The serum concentration of Methallenestril can be decreased when it is combined with Lisinopril. Approved, Investigational Lopinavir The serum concentration of Methallenestril can be decreased when it is combined with Lopinavir. Approved Loteprednol The serum concentration of Loteprednol can be increased when it is combined with Methallenestril. Approved Lumacaftor The serum concentration of Methallenestril can be decreased when it is combined with Lumacaftor. Approved Lumiracoxib Lumiracoxib may increase the thrombogenic activities of Methallenestril. Approved, Investigational ME-609 The serum concentration of ME-609 can be increased when it is combined with Methallenestril. Investigational Medrysone The serum concentration of Medrysone can be increased when it is combined with Methallenestril. Approved Melagatran The serum concentration of Methallenestril can be decreased when it is combined with Melagatran. Experimental Melengestrol The serum concentration of Melengestrol can be increased when it is combined with Methallenestril. Vet Approved Methohexital The therapeutic efficacy of Methallenestril can be decreased when used in combination with Methohexital. Approved Methylphenobarbital The therapeutic efficacy of Methallenestril can be decreased when used in combination with Methylphenobarbital. Approved Methylprednisolone The serum concentration of Methylprednisolone can be increased when it is combined with Methallenestril. Approved, Vet Approved Metreleptin The serum concentration of Methallenestril can be decreased when it is combined with Metreleptin. Approved Mifepristone The therapeutic efficacy of Methallenestril can be decreased when used in combination with Mifepristone. Approved, Investigational Modafinil The serum concentration of Methallenestril can be decreased when it is combined with Modafinil. Approved, Investigational Moexipril The serum concentration of Methallenestril can be decreased when it is combined with Moexipril. Approved Mometasone The serum concentration of Mometasone can be increased when it is combined with Methallenestril. Approved, Vet Approved Mycophenolic acid The serum concentration of Methallenestril can be decreased when it is combined with Mycophenolic acid. Approved N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline The serum concentration of Methallenestril can be decreased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline. Experimental Nabumetone Nabumetone may increase the thrombogenic activities of Methallenestril. Approved Nadroparin Methallenestril may decrease the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat The serum concentration of Methallenestril can be decreased when it is combined with Nafamostat. Approved, Investigational Nafcillin The metabolism of Methallenestril can be increased when combined with Nafcillin. Approved, Investigational NCX 1022 The serum concentration of NCX 1022 can be increased when it is combined with Methallenestril. Investigational Nelfinavir The serum concentration of Methallenestril can be decreased when it is combined with Nelfinavir. Approved Nevirapine The serum concentration of Methallenestril can be decreased when it is combined with Nevirapine. Approved Nitroaspirin The serum concentration of Methallenestril can be decreased when it is combined with Nitroaspirin. Investigational Oleoyl-estrone The serum concentration of Oleoyl-estrone can be increased when it is combined with Methallenestril. Investigational Omapatrilat The serum concentration of Methallenestril can be decreased when it is combined with Omapatrilat. Investigational Ospemifene The risk or severity of adverse effects can be increased when Methallenestril is combined with Ospemifene. Approved, Investigational Otamixaban The serum concentration of Methallenestril can be decreased when it is combined with Otamixaban. Investigational Oxcarbazepine The serum concentration of Methallenestril can be decreased when it is combined with Oxcarbazepine. Approved Paramethasone The serum concentration of Paramethasone can be increased when it is combined with Methallenestril. Approved Parecoxib Parecoxib may increase the thrombogenic activities of Methallenestril. Approved Pentaerythritol Tetranitrate Methallenestril may decrease the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentobarbital The therapeutic efficacy of Methallenestril can be decreased when used in combination with Pentobarbital. Approved, Investigational, Vet Approved Pentosan Polysulfate Methallenestril may decrease the anticoagulant activities of Pentosan Polysulfate. Approved Perindopril The serum concentration of Methallenestril can be decreased when it is combined with Perindopril. Approved Phenindione Methallenestril may decrease the anticoagulant activities of Phenindione. Approved, Investigational Phenobarbital The therapeutic efficacy of Methallenestril can be decreased when used in combination with Phenobarbital. Approved, Investigational Phenprocoumon Methallenestril may decrease the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenytoin The therapeutic efficacy of Methallenestril can be decreased when used in combination with Phenytoin. Approved, Vet Approved Phosphoramidon The serum concentration of Methallenestril can be decreased when it is combined with Phosphoramidon. Experimental Prasterone The risk or severity of adverse effects can be increased when Prasterone is combined with Methallenestril. Approved, Investigational, Nutraceutical Prasterone sulfate The serum concentration of Prasterone sulfate can be increased when it is combined with Methallenestril. Investigational Prednicarbate The serum concentration of Prednicarbate can be increased when it is combined with Methallenestril. Approved, Investigational Prednisolone The serum concentration of Prednisolone can be increased when it is combined with Methallenestril. Approved, Vet Approved Prednisone The serum concentration of Prednisone can be increased when it is combined with Methallenestril. Approved, Vet Approved Pregnenolone The serum concentration of Pregnenolone can be increased when it is combined with Methallenestril. Approved, Experimental, Investigational Primidone The therapeutic efficacy of Methallenestril can be decreased when used in combination with Primidone. Approved, Vet Approved Prinomastat The serum concentration of Methallenestril can be decreased when it is combined with Prinomastat. Investigational Protein C Methallenestril may decrease the anticoagulant activities of Protein C. Approved Protein S human Methallenestril may decrease the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Methallenestril may decrease the anticoagulant activities of Protocatechualdehyde. Approved Prucalopride The serum concentration of Methallenestril can be decreased when it is combined with Prucalopride. Approved Quinapril The serum concentration of Methallenestril can be decreased when it is combined with Quinapril. Approved, Investigational Racecadotril The serum concentration of Methallenestril can be decreased when it is combined with Racecadotril. Investigational Ramipril The serum concentration of Methallenestril can be decreased when it is combined with Ramipril. Approved Remikiren The serum concentration of Methallenestril can be decreased when it is combined with Remikiren. Approved Reviparin Methallenestril may decrease the anticoagulant activities of Reviparin. Approved, Investigational Rifabutin The serum concentration of Methallenestril can be decreased when it is combined with Rifabutin. Approved, Investigational Rifampicin The serum concentration of Methallenestril can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Methallenestril can be decreased when it is combined with Rifapentine. Approved, Investigational Rifaximin The serum concentration of Methallenestril can be decreased when it is combined with Rifaximin. Approved, Investigational Rimexolone The serum concentration of Rimexolone can be increased when it is combined with Methallenestril. Approved Ritonavir The serum concentration of Methallenestril can be decreased when it is combined with Ritonavir. Approved, Investigational Rivaroxaban The serum concentration of Methallenestril can be decreased when it is combined with Rivaroxaban. Approved Rofecoxib Rofecoxib may increase the thrombogenic activities of Methallenestril. Approved, Investigational, Withdrawn Ropinirole The serum concentration of Ropinirole can be increased when it is combined with Methallenestril. Approved, Investigational S-3304 The serum concentration of Methallenestril can be decreased when it is combined with S-3304. Investigational Saquinavir The serum concentration of Methallenestril can be decreased when it is combined with Saquinavir. Approved, Investigational Saxagliptin The serum concentration of Methallenestril can be decreased when it is combined with Saxagliptin. Approved Secobarbital The therapeutic efficacy of Methallenestril can be decreased when used in combination with Secobarbital. Approved, Vet Approved Selegiline The serum concentration of Selegiline can be increased when it is combined with Methallenestril. Approved, Investigational, Vet Approved Simeprevir The serum concentration of Methallenestril can be decreased when it is combined with Simeprevir. Approved Sitagliptin The serum concentration of Methallenestril can be decreased when it is combined with Sitagliptin. Approved, Investigational Sivelestat The serum concentration of Methallenestril can be decreased when it is combined with Sivelestat. Investigational Somatotropin The therapeutic efficacy of Somatotropin can be decreased when used in combination with Methallenestril. Approved, Investigational Spirapril The serum concentration of Methallenestril can be decreased when it is combined with Spirapril. Approved St. John's Wort The therapeutic efficacy of Methallenestril can be decreased when used in combination with St. John's Wort. Approved, Investigational, Nutraceutical Sulodexide Methallenestril may decrease the anticoagulant activities of Sulodexide. Approved, Investigational Telaprevir The serum concentration of Methallenestril can be decreased when it is combined with Telaprevir. Approved, Withdrawn Temocapril The serum concentration of Methallenestril can be decreased when it is combined with Temocapril. Experimental, Investigational Thalidomide Methallenestril may increase the thrombogenic activities of Thalidomide. Approved, Investigational, Withdrawn Theophylline The serum concentration of Theophylline can be increased when it is combined with Methallenestril. Approved Thiamylal The therapeutic efficacy of Methallenestril can be decreased when used in combination with Thiamylal. Approved, Vet Approved Thiopental The therapeutic efficacy of Methallenestril can be decreased when used in combination with Thiopental. Approved, Vet Approved Thiorphan The serum concentration of Methallenestril can be decreased when it is combined with Thiorphan. Experimental Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Methallenestril. Approved Tioclomarol Methallenestril may decrease the anticoagulant activities of Tioclomarol. Experimental Tipranavir Methallenestril may increase the dermatologic adverse activities of Tipranavir. Approved, Investigational Tixocortol The serum concentration of Tixocortol can be increased when it is combined with Methallenestril. Approved, Withdrawn Topiramate The serum concentration of Methallenestril can be decreased when it is combined with Topiramate. Approved Trandolapril The serum concentration of Methallenestril can be decreased when it is combined with Trandolapril. Approved Tranexamic Acid Methallenestril may increase the thrombogenic activities of Tranexamic Acid. Approved Tretinoin The therapeutic efficacy of Methallenestril can be decreased when used in combination with Tretinoin. Approved, Investigational, Nutraceutical Triamcinolone The serum concentration of Triamcinolone can be increased when it is combined with Methallenestril. Approved, Vet Approved Troxerutin Methallenestril may decrease the anticoagulant activities of Troxerutin. Investigational Ubenimex The serum concentration of Methallenestril can be decreased when it is combined with Ubenimex. Experimental, Investigational Ulinastatin The serum concentration of Methallenestril can be decreased when it is combined with Ulinastatin. Investigational Ulobetasol The serum concentration of Ulobetasol can be increased when it is combined with Methallenestril. Approved Ursodeoxycholic acid The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Methallenestril. Approved, Investigational Valdecoxib Valdecoxib may increase the thrombogenic activities of Methallenestril. Approved, Investigational, Withdrawn Vildagliptin The serum concentration of Methallenestril can be decreased when it is combined with Vildagliptin. Approved, Investigational Vitamin C The serum concentration of Methallenestril can be increased when it is combined with Vitamin C. Approved, Nutraceutical Voriconazole The metabolism of Methallenestril can be decreased when combined with Voriconazole. Approved, Investigational Warfarin Methallenestril may decrease the anticoagulant activities of Warfarin. Approved Ximelagatran The serum concentration of Methallenestril can be decreased when it is combined with Ximelagatran. Approved, Investigational, Withdrawn Z-Val-Ala-Asp fluoromethyl ketone The serum concentration of Methallenestril can be decreased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone. Experimental Zofenopril The serum concentration of Methallenestril can be decreased when it is combined with Zofenopril. Experimental - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Compound
- 59084697
- PubChem Substance
- 347829260
- ChemSpider
- 34995295
- Wikipedia
- Methallenestril
- ATC Codes
- G03CC03 — Methallenestril
- G03CC — Estrogens, combinations with other drugs
- G03C — ESTROGENS
- G03 — SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
- G — GENITO URINARY SYSTEM AND SEX HORMONES
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00102 mg/mL ALOGPS logP 4.69 ALOGPS logP 4.72 ChemAxon logS -5.4 ALOGPS pKa (Strongest Acidic) 4.53 ChemAxon pKa (Strongest Basic) -4.8 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 46.53 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 83.11 m3·mol-1 ChemAxon Polarizability 32.23 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Naphthalenes
- Sub Class
- Not Available
- Direct Parent
- Naphthalenes
- Alternative Parents
- Anisoles / Alkyl aryl ethers / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Naphthalene / Phenol ether / Anisole / Alkyl aryl ether / Monocarboxylic acid or derivatives / Ether / Carboxylic acid / Carboxylic acid derivative / Organic oxygen compound / Organic oxide
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- Not Available
Drug created on November 04, 2016 15:36 / Updated on March 02, 2018 04:21